The treatment landscape for hemophilia has evolved rapidly over the past decade, with the approval of several therapies with novel mechanisms of action. Extended half-life factor concentrates and nonfactor therapies, including factor VIII mimetics and rebalancing agents, have reduced treatment burden while also improving bleed protection. Although these new therapies provide an unprecedented ability to personalize treatment and to meet changing needs across the life span for each individual, the complexity of these treatment considerations has made clinical decision-making and selection of the optimal treatment challenging for those living with hemophilia and their clinicians.

1.
Mannucci
PM.
Hemophilia treatment innovation: 50 years of progress and more to come
.
J Thromb Haemost
.
2023
;
21
(
3
):
403
-
412
.
Google Scholar
 
2.
Mahlangu
J
,
Powell
JS
,
Ragni
MV
, et al; A-LONG Investigators.
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
.
Blood
.
2014
;
123
(
3
):
317
-
325
.
Google Scholar
 
3.
Powell
JS
,
Pasi
KJ
,
Ragni
MV
, et al; B-LONG Investigators.
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B
.
N Engl J Med
.
2013
;
369
(
24
):
2313
-
2323
.
Google Scholar
 
4.
Pipe
SW
,
Leebeek
FWG
,
Recht
M
, et al.
Gene therapy with etranacogene dezaparvovec for hemophilia B
.
N Engl J Med
.
2023
;
388
(
8
):
706
-
718
.
Google Scholar
 
5.
Ozelo
MC
,
Mahlangu
J
,
Pasi
KJ
, et al; GENEr8-1 Trial Group.
Valoctocogene roxaparvovec gene therapy for hemophilia A
.
N Engl J Med
.
2022
;
386
(
11
):
1013
-
1025
.
Google Scholar
 
6.
Konkle
BA
,
Stasyshyn
O
,
Chowdary
P
, et al.
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
.
Blood
.
2015
;
126
(
9
):
1078
-
1085
.
Google Scholar
 
7.
Reding
MT
,
Ng
HJ
,
Poulsen
LH
, et al.
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII
.
J Thromb Haemost
.
2017
;
15
(
3
):
411
-
419
.
Google Scholar
 
8.
Giangrande
P
,
Andreeva
T
,
Chowdary
P
, et al; Pathfinder™2 Investigators.
Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A
.
Thromb Haemost
.
2017
;
117
(
2
):
252
-
261
.
Google Scholar
 
9.
Collins
PW
,
Young
G
,
Knobe
K
, et al; paradigm 2 Investigators.
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
.
Blood
.
2014
;
124
(
26
):
3880
-
3886
.
Google Scholar
 
10.
Santagostino
E
,
Martinowitz
U
,
Lissitchkov
T
, et al; PROLONG-9FP Investigators Study Group.
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
.
Blood
.
2016
;
127
(
14
):
1761
-
1769
.
Google Scholar
 
11.
Mahlangu
J
,
Kuliczkowski
K
,
Karim
FA
, et al; AFFINITY Investigators.
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A
.
Blood
.
2016
;
128
(
5
):
630
-
637
.
Google Scholar
 
12.
Reding
MT
,
Álvarez-Román
MT
,
Castaman
G
, et al.
Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
.
Eur J Haematol
.
2024
;
112
(
2
):
286
-
295
.
Google Scholar
 
13.
von Drygalski
A
,
Chowdary
P
,
Kulkarni
R
, et al; XTEND-1 Trial Group.
Efanesoctocog alfa prophylaxis for patients with severe hemophilia A
.
N Engl J Med
.
2023
;
388
(
4
):
310
-
318
.
Google Scholar
 
14.
Malec
L
,
Peyvandi
F
,
Chan
AKC
, et al; XTEND-Kids Trial Group.
Efanesoctocog alfa prophylaxis for children with severe hemophilia A
.
N Engl J Med
.
2024
;
391
(
3
):
235
-
246
.
Google Scholar
 
15.
Kitazawa
T
,
Igawa
T
,
Sampei
Z
, et al.
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
.
Nat Med
.
2012
;
18
(
10
):
1570
-
1574
.
Google Scholar
 
16.
Callaghan
MU
,
Negrier
C
,
Paz-Priel
I
, et al.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
.
Blood
.
2021
;
137
(
16
):
2231
-
2242
.
Google Scholar
 
17.
Mahlangu
J
,
Jiménez-Yuste
V
,
Ventriglia
G
, et al.
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
.
Res Pract Thromb Haemost.
2024
;
8
(
2
):
102364
.
Google Scholar
 
18.
Valentino
LA
,
Santaella
ME
,
Carlson
SA
,
Recht
M
.
Contemporary approaches to treat people with hemophilia: what's new and what's not?
Res Pract Thromb Haemost
.
2025
;
9
(
1
):
102696
.
Google Scholar
 
19.
Mancuso
ME
.
Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: phase 3, open-label, randomized, controlled, FRONTIER2 study
.
Paper presented at: ISTH Congress 2024
;
June 22-26, 2024
;
Bangkok
.
20.
Teranishi-Ikawa
Y
,
Soeda
T
,
Koga
H
, et al.
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state
.
J Thromb Haemost
.
2024
;
22
(
2
):
430
-
440
.
Google Scholar
 
21.
Lamb
YN.
Marstacimab: first approval
.
Drugs
.
2025
;
85
(
2
):
263
-
269
.
Google Scholar
 
22.
Keam
SJ.
Concizumab: first approval
.
Drugs
.
2023
;
83
(
11
):
1053
-
1059
.
Google Scholar
 
23.
Matino
D
.
Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors
.
Paper presented at ISTH Congress 2025
;
June 21-25, 2025
,
Washington DC
.
24.
Young
G
,
Lenting
PJ
,
Croteau
SE
,
Nolan
B
,
Srivastava
A
.
Antithrombin lowering in hemophilia: a closer look at fitusiran
.
Res Pract Thromb Haemost.
2023
;
7
(
4
):
100179
.
Google Scholar
 
25.
Josset
L
,
Rezigue
H
,
Dargaud
Y.
Thrombin generation assay to support hematologists in the era of new hemophilia therapies
.
Int J Lab Hematol
.
2025
;
47
(
2
):
212
-
220
.
Google Scholar
 
26.
Jiménez-Yuste
V.
Non-factor therapies for hemophilia: achievements and perspectives
.
Semin Thromb Hemost
.
2025
;
51
(
1
):
23
-
27
.
Google Scholar
 
27.
Coffin
D
,
Skinner
MW
,
Thornburg
CD
, et al.
Development of the World Federation of Hemophilia shared decision-making tool
.
Haemophilia
.
2024
;
30
(
6
):
1298
-
1308
.
Google Scholar
 
28.
Makris
M
,
O'Mahony B. Hemophilia treatments and the paradox of choice
.
Res Pract Thromb Haemost
.
2025
;
9
(
2
):
102726
.
Google Scholar
 
Copyright © 2025 by The American Society of Hematology
2025
You do not currently have access to this content.